Gail F. Lieberman has demonstrated professional experience in strategy, finance, M&A, compensation, and technology for a wide range of industry sectors, and she combines judgment, experience, and knowledge in a collaborative manner that adds value to board matters. Her board experience includes serving as a director and chair or member of audit, compensation, and nominating and governance committees for public and private companies in the technology, life sciences, manufacturing, materials, security, financial services, and utilities sectors.

Among her current roles, Lieberman has served on the board of directors for security and technology firm ICTS International N.V. (OTCBQC: ICTSF) since 2010 with roles that include chair of the compensation committee and member of the audit committee. In the financial technology industry, she has served on the board for Thesys Group since 2015 and for EquiLend since 2019, with roles for the latter that include lead director and chair of the nominating and governance, and compensation committee. Since 2017, she has served on the board for W. L. Gore & Associates, including as chair of the audit and finance committee.

She began her board service career in 2004 with health-care company i-Trax Inc. (Amex: DMX), including as chair of the audit committee and member of the compensation and strategy committees. Her service there ended in April 2008 with the company’s sale to Walgreens at a 40 percent premium. In 2005, she joined the boards of TriPath Imaging Inc. (Nasdaq: TPTH), a medical devices and manufacturing company, and manufacturing company Breeze-Eastern Corp. (Amex: BZC). At TriPath Imaging, she was a member of the audit and governance committees; her service ended in December 2006 when the company was sold to Becton Dickenson at an 81 percent premium. At Breeze-Eastern, she was chair of the audit committee and a member of the strategy committee. From 2005 until her tenure ended in 2007, Breeze-Eastern’s price per share rose from $6 to $12. She continued as advisor to the board until 2008. Lieberman was on the board of life sciences company Dara Biosciences Inc. (Nasdaq: DARA) from 2009 until its sale in February 2015 to Midatech at a 50 percent premium; during her tenure there, she was chair of the compensation committee and a member of the audit and nominating committees. In 2010, she joined the board for financial technology firm FTEN, including as member of the audit committee, until its sale to Nasdaq in December 2010. Most recently, she served with the South Central Connecticut Regional Water Authority, including as chair of the strategy committee, from 2012 to 2016. In addition, she was a proposed director as part of Exelon’s bid for NRG.

Lieberman was the former CEO of Liquid Alternatives (Schroders) as well as chief financial officer for Thomson Corp.’s financial and professional publishing division, for Moody’s Investor Service (D&B), and for Scali, McCabe, Sloves (The Ogilvy Group). She has domestic and international operating and mergers and acquisitions (M&)experience in stand-alone as well as large multidivisional and multinational companies. She is currently managing partner of Rudder Capital, where she advises service-, media-, and technology-sector companies on corporate finance alternatives and strategy.

Lieberman holds a bachelor of arts in mathematics and physics and a master of business administration in finance from Temple University.